Cas13d-mediated viral RNA degradation leads to potent antiviral control against both positive and negative sense RNA viruses
Year: 2026
Type: article
Abstract: Respiratory viral infections continue to pose a substantial global health challenge, with a pressing need for effective treatment options. The rapid mutation rate of RNA viruses presents a significant risk of escape from existing treatments. Here, we harness the rapid adaptability and high sequence specificity of the RNA-targeting CRISPR-Cas13 nuclease technology to target and cleave the genome of different RNA viruses, disrupting replication and impairing propagation. We identified potent CRISPR-RfxCas13d/crRNA (Cas13d/crRNA) combinations that can efficiently restrict viral replication in both pre- and post-viral exposure treatment settings. In vitro treatment with lipid nanoparticles (LNPs) co-encapsulating Cas13d mRNA and crRNAs targeting coding and non-coding regions of positive-sense (+) RNA coronaviruses including SARS-CoV-2 effectively inhibited viral replication. In addition, both pre- and post-viral exposure treatments with the LNP-Cas13d/crRNA against the negative-sense (−) RNA Nipah virus resulted in 99% restriction of this highly pathogenic virus. Hence, the Cas13d/crRNA antiviral method holds promise as a potential therapeutic approach against severe viral infections caused by both (+) and (−) RNA viruses. Furthermore, the multi-locus targeting of viruses by Cas13d could offer a possibility to prevent virus breakthrough and increase the therapeutic arsenal against many emerging RNA viruses in the future.
Institutions: Medizinische Hochschule Hannover, Lyon 1 Université, École Normale Supérieure de Lyon, Centre National de la Recherche Scientifique, Inserm, Centre International de Recherche en Infectiologie, Helmholtz Centre for Infection Research, Center for Experimental and Clinical Infection Research, Shanghai Jiao Tong University, Renji Hospital, Centre for Individualised Infection Medicine
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,900
OpenAlex ID: W7222965639
